Marco Meglio

Over a 12-month treatment period, patients on deferiprone demonstrated decreased blood ferritin and hippocampal QSM but caused accelerated cognitive decline and increased regional brain atrophy.

The trial, a 20-week study assessing lamotrigine in DLB, will use change in Clinical Dementia Rating-Sum of Boxes as the primary efficacy end point, with several other notable secondary outcomes.

For more than a 2-year treatment period, 95% of patients reported taking at least 95% of their daily medications with zilucoplan.

The neurologist in the Headache Center at Cleveland Clinic shared her post perspective on the 2024 AHS Scottsdale meeting which highlighted advancements in headache medicine and the growing impact of the field on patient care. [WATCH TIME: 5 minutes]

The professor of neurology and radiology at University of California, San Francisco, discussed the potential of blood-based biomarkers in Alzheimer treatment eligibility, highlighting current limitations and the importance of safety monitoring. [WATCH TIME: 7 minutes]

Overall, subcutaneous efgartigimod was safe and effective in patients with seropositive MG, demonstrated by consistent improvements in Myasthenia Gravis-Activites of Daily Living.

Findings from a recently published study suggest patients with Parkinson disease can reduce postural sway as efficiently as neurologically healthy patients when performing horizontal saccades.

The multicenter, 24-week study will feature 20 patients with MG, testing changes on MG-ADL as well as several other secondary outcomes, including patient-reported assessments.

The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.

Amanda Hare, DNP, a doctor of nursing practice specialized in movement disorders, gave comments on the innovation behind the StrivePD app and how it can revolutionize personalized treatment management for patients with Parkinson disease.